The Thalidomide Tragedy β A Turning Point in Pharmacovigilance
1957 β Thalidomide was first marketed in West Germany as a sedative and treatment for morning sickness in pregnant women.
Late 1950s β Early 1960s β Widely prescribed in Europe, Asia, Africa, and other regions.
At the time, drug safety regulations were not as strict as they are today.
The consequences were:
Over 10,000 children were born with severe birth defects, particularly
limb deformities (Phocomelia- A rare condition)
Many more pregnancies ended in miscarriages and stillbirths.
Other deformities like ear, heart, and organ malformations.
Immediate Action β The drug was withdrawn from markets worldwide.
This tragedy became a wake-up call for the world. It led to:
Stricter drug approval processes.
Establishment of global pharmacovigilance systems.
A culture of continuous safety monitoring.
Interestingly, thalidomide was later reintroduced under strict controls for the
leprosy and multiple myeloma Condition.
The actual pharmacovigilance starts after thalidomide tragedy.
The thalidomide incident reminds us why drug safety can never be taken for granted.
MBH/PS